Neurocrine Biosciences chief corporate affairs officer sells $82,820 in stock

David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.7 billion biopharmaceutical company with strong financial health indicators including a robust current ratio of 3.4, recently executed a series of stock transactions, as disclosed in a Form 4 filing with the Securities and Exchange Commission. On February 10, Boyer sold 700 shares of common stock, generating total proceeds of approximately $82,820. The shares were sold at a weighted average price of $118.31, with individual sale prices ranging from $116.08 to $123.53. The transaction comes as the stock trades near its 52-week low, with InvestingPro analysis suggesting the shares may be undervalued.

The sales were conducted under a Rule 10b5-1 trading plan, which Boyer adopted in June 2021. This plan allows insiders to set up a predetermined schedule for selling shares, helping to avoid potential conflicts of interest. Following these transactions, Boyer holds 1,998 shares of Neurocrine Biosciences stock.

Additionally, on February 8, Boyer acquired 1,329 shares of common stock through the vesting of Restricted Stock Units (RSUs) at no cost. This transaction did not involve any cash exchange and was part of a previously established compensation plan. For deeper insights into NBIX’s valuation and 12 additional exclusive ProTips, visit InvestingPro, where you’ll find comprehensive research reports and expert analysis.

In other recent news, Neurocrine Biosciences has been the subject of several analyst notes following its latest earnings report. Deutsche Bank (ETR:DBKGn) initiated coverage of Neurocrine with a Hold rating and a price target of $138, citing the fair valuation of the company’s stock given current market capitalization and the performances of its treatments, Ingrezza and Crensessity. The bank’s analyst noted projections for US peak sales of Ingrezza at around $3.0 billion and Crensessity at about $615 million.

UBS, on the other hand, maintained a Buy rating on Neurocrine but lowered its price target to $154 from $176. The adjustment was in response to a significant decline in the company’s shares and lower-than-anticipated guidance for Ingrezza. Despite the reduction, UBS expressed confidence in the stock’s potential for future gains.

Guggenheim also maintained a Buy rating but lowered its price target to $163 from $165 following Neurocrine’s fourth-quarter sales report, which showed Ingrezza sales slightly below consensus estimates. H.C. Wainwright maintained a Buy rating on Neurocrine Biosciences but adjusted the price target to $185 from $190, following the company’s announcement of Ingrezza’s revenue and the lower-than-expected full-year 2025 Ingrezza revenue guidance.

These developments reflect the ongoing market analysis and investor interest in Neurocrine Biosciences, as the company continues to navigate the competitive landscape and advance its clinical pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.